Murali Mohan Chakinala

Murali Mohan Chakinala, MD

  • Lung Health (Pulmonology)

Sees Patients For

Pulmonary hypertension,thromboembolic disease, hereditary hemorrhagic telangiectasias, pulmonary arteriovenous malformations

Patients Seen At

Hospital Affiliations

  • Barnes-Jewish Hospital

Board Certifications

  • Internal Medicine
  • Pulmonary Disease
  • Critical Care

Academic Title(s)

Professor, Medicine
Division of Pulmonary and Critical Care Medicine


  • English



2002 Pulmonary And Critical Care Medicine, Washington University School of Medicine, St. Louis, Missouri


1997 Internal Medicine, University of Texas, Southwestern Medical Center, Dallas, Texas

Medical Degree

1994 Vanderbilt University School of Medicine, Nashville, Tennesee


1990 Economics, Duke University, Durham, North Carolina

Publications & Research

Search PubMed for publications »

Financial Disclosures

Disclosure of Financial Interests with Industry

Washington University and its physicians and health professionals are committed to ensuring integrity and objectivity in medical decision-making. Some of our physicians and health professionals work collaboratively with pharmaceutical, medical device or other medical care related companies to develop innovative ideas and products that can improve health care delivery and clinical outcomes for patients. In some instances, our physicians and health professionals have an ownership or potential ownership interest in a commercial company; and/or are paid by a commercial company to provide advice on product design or to speak about the use of medications, devices, equipment or procedures. These payments may include: a) compensation for consulting and speaking engagements, b) equity, and/or c) royalties for products invented by our faculty. Any payments to Washington University physicians or health professionals must be based on tangible services and may not exceed fair market value for their work. In addition to disclosure on this website, physicians and health professionals earning more than $10,000 per year must disclose their corporate financial relationship in writing to patients when prescribing or using that company's products.